Overview

In medicine, endocrinology is perhaps the domain that encompasses the most molecular imaging using radioactive agents, also called radiopharmaceuticals. This is due to the diversity of molecular targets, including hormone synthesis pathways expressed uniquely by endocrine tumors and the growing knowledge in their pathophysiology and genetics. Those radiopharmaceuticals not only serve as diagnostic agents, but can also serve as a platform for characterizing endocrine disorders and treat patients and be used to monitor intracellular events that are induced by various therapies. Finally, they may be able to predict the aggressiveness and metastatic potential of endocrine tumors. This book provides comprehensive and up-to-date insights into the diagnostic, therapeutic, and future approaches of nuclear medicine to endocrine tumors in a new spirit of precision medicine. It will be of interest to practicing physicians, including nuclear medicine specialists, radiologists, endocrinologists, and oncologists, as well as fellows in training, students, and other health care professionals.

Full Product Details

9781527565203

Table of Contents

Reviews

Author Information

Dr David Taieb, MD, PhD, is Full Professor of Nuclear Medicine at la Timone hospital, associated with Aix-Marseille University, France. He is the author of over 200 peer-reviewed publications. A major focus of his clinical research in collaboration with the NIH, has been the relationship between imaging phenotypes and genotypes in pheochromocytoma and paraganglioma (PPGL). In addition, he is actively involved in targeted radionuclide therapy with a major focus on endocrine neoplasms. He is also affiliated to the French Institute of Health and Medical Research with several ongoing research projects on castration-resistant prostate cancer and nanotheranostics.Dr Karel Pacak is the Chief of the Section on Medical Neuroendocrinology at the National Institute of Child Health and Human Development, USA. He is recognized for patient-oriented pheochromocytoma/paraganglioma (PPGL) research, and he has described the role of a new HIF2A somatic mutation in paraganglioma, somatostatinoma, and polycythemia (Pacak-Zhuang syndrome). Alongside his colleagues, he also introduced novel imaging algorithms in the assessment and localization of PPGL. He has received awards from the International Association of Endocrine Surgeons, the Australian Endocrine Society, the Irish Endocrine Society, and the PheoPara Alliance, and is a recipient of the Gold Jessenius Medal from the Slovak Academy of Sciences, the Purkyne Medal from the Czech Medical Society, and the Directors' Award from the NIH/NICHD. He has published more than 600 peer-reviewed articles and 110 book chapters.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available